Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anbenitamab - Alphamab

Next Previous
Drug Profile

Anbenitamab - Alphamab

Alternative Names: anti-HER2-bsAb - Alphamab; KN-026

Latest Information Update: 31 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab
  • Developer Jiangsu Alphamab Biopharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 positive breast cancer
  • Phase II/III Gastric cancer
  • Phase II Breast cancer; Solid tumours

Most Recent Events

  • 27 Dec 2024 Shanghai JMT-Bio plans a phase III trial for HER2-positive-breast cancer (Neoadjuvant therapy) in December 2024 (NCT06747338)
  • 16 Dec 2024 Phase-III clinical trials in HER2-positive-breast-cancer (Combination therapy, Late-stage disease, Neoadjuvant therapy) in China (IV) (NCT06747338)
  • 13 Sep 2024 Efficacy and adverse event data from a phase II/III trial in Gastroesophageal cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top